Regulatory approval

Published by the Health Service Executive. Approved

Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor

This is written in the approval document.

Reimbursement

CDS

Citation

Venetoclax Monotherapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6973/400_v3_Venetoclax_Monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	not 17p deletion	Chronic Lymphocytic Leukemia	Venetoclax
HSE (1)	Wild type TP53	Chronic Lymphocytic Leukemia	Venetoclax

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2018-12-01	Health Service Executive	Indication approved for reimbursement.